North America Blood Irradiation Market

The blood irradiation market in North America is expected to grow from US$ 29.02 million in 2022 to US$ 42.61 million by 2028. It is estimated to grow at a CAGR of 6.6% from 2022 to 2028.

 Increase in Communicable and Noncommunicable Disease Prevalence Favors North America Blood

Irradiation Market Growth

In North America, there has been a rise in the incidence of blood transfusion procedures owing to the surge in surgical procedures, accidents, trauma cases, and disorders; and the rising prevalence of bloodstream infections. Bloodstream infections are the major cause of illness and death among large populations. Bloodstream infections, as well as underlying conditions, and invasive procedures are common among the geriatric population. The rising awareness about these infections and elevated immune response to transfused blood can lead to complications. There is a high prevalence of communicable and noncommunicable diseases, including cancer, cardiovascular disorders, chronic renal disease, and stroke, in North American countries. Blood transfusion may be a common step adopted during the treatment of these diseases. Cellular blood components are irradiated before undertaking the transfusion process. The irradiation prevents transfusion associated-graft versus host disease (TA-GVHD) among recipients by averting the proliferation of viable T lymphocytes. The increasing use of irradiated blood for the treatment of cancer patients strengthens the immune system and improves overall health.

Market Overview

The North American blood irradiation market has been segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2022. The US accounts for a significant share of the blood irradiation market in North America. Increasing demand for organ transplantation followed by increasing prevalence of both communicable and non-communicable diseases is likely to increase the demand for blood irradiation market. The four major diseases responsible for the death in the United States are Cardiovascular diseases, Diabetes, Cancer and Chronic respiratory diseases. Thus, the increasing research and development in the country is anticipated to boost the US blood irradiation market growth during the forecast period.

North America Blood Irradiation Market Revenue and Forecast to 2028 (US$ Million)

North America Blood Irradiation Market  Segmentation

The North America blood irradiation market is segmented into type, indication, end user, and country.

• Based on type, the market is segmented into intravenous laser blood irradiation, transcutaneous laser blood irradiation, and extracorporeal blood irradiation. The intravenous laser blood irradiation segment registered the largest market share in 2022.
• Based on indication, the North America blood irradiation market is segmented into acute leukemia, lymphoma, solid tumors, pelvic tumors, and others. The acute leukemia segment held the largest market share in 2022.
• Based on end user, the market is segmented into hospitals, blood banks, diagnostics clinics, and research institutes. The hospital segment held the largest market share in 2022.
• Based on country, the North America blood irradiation market is segmented into the US, Canada, Mexico; the US dominated the market in 2022.

Hitachi, Ltd.; Best Theratronics Ltd.; Rad Source Technologies; Gilardoni S.p.A.; Typenex Medical, and Actemium are the leading companies operating in the blood irradiation market in the region.   

North America Blood Irradiation Market Strategic Insights

North America Blood Irradiation Market Segmentation Analysis

North America Blood Irradiation Market Report Highlights

North America Blood Irradiation Report Scope

North America Blood Irradiation Market Country and Regional Insights